Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 22;12(1):118. doi: 10.1038/s41419-021-03398-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Silver staining of anti-HA-CSN6 in a co-IP assay. B Interaction of endogenous CSN6 with endogenous CDK9. Equal amounts of A375 and MV3 cell lysates were immunoprecipitated with the indicated antibodies and immunoblotted with anti-FLAG and anti-CDK9 antibodies. C Total cellular extracts from CSN6-knockdown and CSN6-rescued CSN6-knockdown A375 and MV3 cells and control cells were prepared and subjected to western blotting using the indicated antibody. D The CDK9 turnover rate of CSN6-overexpressing cells was determined. A375 and MV3 cells overexpressing CSN6 were treated with CHX (100 μg/ml) at the indicated time points before whole-cell lysates were collected for immunoblot analysis. The turnover of CDK9 is indicated graphically. E Cell lysates were prepared from CSN6-knockdown A375 and MV3 cells treated with or without MG132 for 8 h. Equal amounts of cell lysates were immunoblotted with the indicated antibodies.